DoD Multiple Sclerosis, Exploration - Hypothesis Development Award | HT9425 23 MSRP EHDA

Opportunity Information: Apply for HT9425 23 MSRP EHDA

The Department of Defense Multiple Sclerosis Research Program (MSRP) Exploration - Hypothesis Development Award (EHDA) is a research funding opportunity intended to help investigators test bold, early-stage ideas in multiple sclerosis (MS) that are high-risk but could produce high-impact breakthroughs. The core purpose is to support the initial exploration of concepts that are not yet proven and may be outside mainstream approaches, with the expectation that successful projects will create a strong foundation for future, more extensive studies and follow-on funding. In other words, this mechanism is meant for generating credible new scientific directions rather than extending an already well-established line of work.

A central requirement is that the proposed project is built around a clear, testable hypothesis supported by strong scientific rationale and a sound study design. Importantly, applicants are not required to include preliminary results or prior published data to justify feasibility, which makes this award particularly aligned with true hypothesis development and concept testing. That said, the proposal still needs to be rigorous in how it plans to evaluate the hypothesis, including appropriate experimental strategy, controls, and a logical pathway from results to interpretation.

Innovation is the defining feature of this award. The DoD is explicitly looking for research that introduces a novel paradigm, challenges existing assumptions in MS, reframes known problems from a new angle, or demonstrates a high level of creativity. Proposals that are mainly incremental, such as small extensions of current projects or straightforward next steps based heavily on existing literature, are described as inconsistent with the intent of the EHDA. Because of that, the Principal Investigator (PI) is expected to directly and plainly explain what is innovative about the project and why it matters to the MS field, rather than assuming reviewers will infer novelty on their own.

For applications aligned with the focus area titled "Correlates of Disease Activity and Progression in MS," there is an additional practical expectation: applicants must show that they already have access to the specimens and/or data needed for the cohort they plan to study. This is not just a general statement of intent; the opportunity points applicants to a specific requirement for letter(s) confirming access to specimens and/or data. This emphasis signals that while preliminary scientific data are not required, access to the necessary materials for the proposed work must be credible and documented when the project depends on a specific dataset or biorepository.

The announcement also flags special considerations for projects using animal models of MS. Applicants are expected to choose models carefully and justify why the selected model is relevant to the particular human MS feature being investigated. Since different MS models capture different aspects of the disease (for example, inflammatory demyelination versus neurodegeneration or progressive features), the program wants applicants to demonstrate that the model is not chosen by habit or convenience, but because it is appropriate for the scientific question being asked.

A notable feature of this opportunity is the dedicated New Investigator option, which is meant to encourage early-career researchers who are building independence in MS research. The goal is to help promising investigators early in faculty appointments continue developing their research programs. Applications submitted under the New Investigator track are reviewed separately from those submitted by Established Investigators, which can reduce direct competition with long-established laboratories. New Investigators are also encouraged to strengthen proposals through collaborations, especially with researchers who bring MS-specific expertise or other relevant technical or clinical strengths, supported by evidence such as prior funding and publications.

From an administrative standpoint, the opportunity is run by the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity number is HT9425-23-MSRP-EHDA. It is listed under CFDA 12.420 and falls within science and technology and other research and development activities. The program allows for funding through grants and cooperative agreements. Eligibility is described as unrestricted, meaning it is broadly open to applicants of any entity type, subject to any additional eligibility clarifications in the full announcement. The original posting date was April 14, 2023, with an original closing date of October 6, 2023. The announcement anticipates approximately eight awards, and the listed award ceiling is shown as 0, which typically indicates that applicants must refer to the full solicitation for budget limits or that caps may vary by topic or be otherwise specified outside the summarized fields.

Overall, the EHDA is best understood as an engine for new MS research directions: it prioritizes originality, explicitly tolerates early-stage uncertainty by not requiring preliminary data, and expects applicants to present a sharply defined hypothesis with a strong plan for testing it. It also puts practical guardrails in place where needed, such as requiring documented access to cohorts for certain research areas and demanding thoughtful justification of animal model relevance, while creating a distinct on-ramp for early-career investigators through the New Investigator option.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Multiple Sclerosis, Exploration - Hypothesis Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 14, 2023.
• Applicants must submit their applications by Oct 06, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 MSRP EHDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: